Teva Pharmaceutical (TEVA): Bullish Uptrend Signals Continuation Potential
Key Takeaways
- TEVA exhibits a long-term uptrend, with price trading above key exponential moving averages including the 50-day EMA at $29.62 and 100-day EMA at $29.84, though below the 200-day EMA near $30.50.
- Recent price action shows consolidation in a bull pennant pattern on the daily chart following a breakout above the 200-day moving average, signaling potential continuation higher.
- RSI(14) at 57.27 indicates buy momentum without overbought conditions; MACD(12,26) at 0.15 with buy signal supports bullish bias.
- Immediate support at $30.03 (pivot S1) and $29.92 (S3); resistance at $30.15 (R1) and $30.26 (R3).
- Overall technical summary leans buy, driven by 9 buying moving averages versus 3 selling.
Assessing the Trend
I've been tracking TEVA, the stock of Teva Pharmaceutical Industries, as it builds a multi-year up-channel after reversing from a prolonged bottom. From what I see on the daily chart, the structure remains solidly bullish, with price having broken decisively above the 200-day moving average. Shorter-term, it holds an uptrend, positioned above most simple and exponential moving averages, such as the MA20 at $29.95 and MA50 at $29.52. A recent pullback has it testing dynamic support near the 20-day MA, which aligns with channel lows noted in trader analyses on platforms like TradingView. One thing that stands out is the declining volume during this consolidation, which often builds pressure for the next upward leg.
Critical Support and Resistance Zones
Traders watching TEVA are paying close attention to pivot-derived levels. Classic pivots show immediate support at S1 $30.03, S2 $29.98, and S3 $29.92, with the pivot point at $30.09 serving as a neutral zone. Resistance levels are at R1 $30.15, R2 $30.20, and R3 $30.26. Broader analysis reveals confluence around $29.40-$29.62, where the MA100 and MA50 create a strong demand zone. Upside resistance ties into prior channel highs near $30-$32, capped by the 50-day SMA at $32.14 (from volume-weighted data) and the 200-day EMA. Deeper supports from TradingView ideas sit at volume bases of $22-$25 and historical lows near $12.67, but near-term focus stays on $29.50-$30.
Momentum Under the Hood
The RSI(14) for Teva Pharmaceutical Industries (TEVA) stands at 57.266, placing it firmly in buy territory—bullish yet not overheated. MACD(12,26) registers a positive 0.15 with a buy signal, pointing to sustained momentum. STOCHRSI(14) at 19.434 hints at short-term oversold conditions within the uptrend, which could set up a bounce. ADX(14) at 27.333 confirms decent trend strength. These readings align with a neutral Stochastic %K at 54 and Williams %R at -48, suggesting healthy momentum even amid recent pullbacks. I also checked this using Tickeron’s AI Screener to compare how the stock stacks up against industry peers.
Unpacking Recent Price Action and Patterns
In my view, TEVA has demonstrated resilient price action over the last 30 days, posting significant upside—up to 85% in some phases—before entering healthy consolidation. A textbook bull pennant has formed on the daily timeframe after the impulse wave, with key EMAs (50/100/200) aligned bullishly below price. Volume has tapered off inside the pattern, which is typical for continuation setups, while earlier spikes validated breakouts from descending channels. Gap fills around $21.40 have cleared key hurdles, paving the way for higher moves. This setup suggests accumulation is underway, positioning for a potential push toward the channel's upper bounds.
AI Daily Buy/Sell Signals
I’ve found Tickeron’s AI Daily Buy/Sell Signals particularly useful in my analysis of stocks like Teva Pharmaceutical Industries (TEVA). These signals draw on artificial intelligence to analyze massive datasets, including technical indicators, price patterns, and historical behaviors. Machine learning algorithms help identify emerging trends, momentum shifts, and probabilistic entry/exit points based on pattern recognition and statistical backtesting. In practice, I use them to confirm chart breakouts, assess overbought/oversold levels akin to RSI, or time trades around MACD crossovers. They provide neutral, data-driven insights that enhance decision-making without promising results. I’m watching the TEVA signals closely to refine my strategy.
Outlook and Levels to Monitor
For TEVA, I think the key is a breakout above pennant resistance near $30.15-$30.26, which could extend the up-channel toward prior highs around $32. Holding above $29.92 support preserves the bullish structure, while pullbacks to $29.50 MA confluence present potential dip-buy opportunities. Keep an eye on RSI for any divergence, MACD for fading crossovers, and volume for move confirmation. A breakdown below $29.92 might test deeper supports at $28-$29, prompting a channel retest. This is important because pivot breaks, EMA alignments, and pennant resolution will dictate the next phase.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
TEVA in upward trend: price may ascend as a result of having broken its lower Bollinger Band on March 12, 2026
TEVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 40 cases where TEVA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TEVA's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on March 31, 2026. You may want to consider a long position or call options on TEVA as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TEVA just turned positive on March 31, 2026. Looking at past instances where TEVA's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in of 302 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for TEVA crossed bearishly below the 50-day moving average on March 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for TEVA entered a downward trend on April 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.537) is normal, around the industry mean (29.061). P/E Ratio (25.471) is within average values for comparable stocks, (63.964). Projected Growth (PEG Ratio) (1.534) is also within normal values, averaging (2.025). TEVA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (2.077) is also within normal values, averaging (109.144).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients
Industry PharmaceuticalsGeneric
Advertisement